CV · CapsoVision, Inc · Webcasts, Transcripts & Audio
$6.45
+0.28 (+4.54%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company, having evaluated the extant facts and circumstances, concluded that the facts and circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date of issuance of these financial statements. While the Company raised approximately $14 million in gross proceeds resulting from the Private Placement described in Note 1. DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE and further discussed in Note 9. COMMON STOCK, it is not probable that these funds are sufficient to fund expenditures necessary to achieve sales growth and innovation objectives. The Company intends to consummate additional capital raising activities, but there is no certainty as to such capital raising activities occurring at all, or occurring with sufficient timing or magnitude, sufficient to alleviate such substantial doubt.”View the 10-Q filed Aug 13, 2026
Market Cap
$321.30M
Shares
50.05M
Volume · Oct 5
27.4K
Avg daily vol (3M)
166.68K
CapsoVision, Inc Webcasts
Earnings calls, investor updates, investor days and conferences for CapsoVision, Inc (CV), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
Earnings call
FY26 · Q2
2026-08-13
CapsoVision, Inc (CV) Q2 2026 Earnings Call Transcript
Confident tone
CapsuCam Colon development
FDA clearance of AI Highlights
CapsuCam Plus commercial growth
Revenue
$3.64M
▲ 9.9% YoY Diluted EPS
$-0.15
Gross margin
51.4%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
CapsoVision, Inc (CV) Q1 2026 Earnings Call Transcript
Positive tone
AI-assisted reading (AI Highlights)
CAPSO-10 UGI / pancreatic cancer program
Commercial / installed base performance
Revenue
$2.79M
▲ 0.3% YoY Diluted EPS
$-0.15
Gross margin
47.6%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
CapsoVision, Inc (CV) Q4 2025 Earnings Call Transcript
Confident tone
FDA regulatory pathway and timing
CapsuleCam UGI / pancreatic cancer initiative
CapsuleCam Colon Gen2 program
Revenue
$3.92M*
Gross margin
49.9%
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-03-23
CapsoVision, Inc (CV) March 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-13
CapsoVision, Inc (CV) Q3 2025 Earnings Call
Revenue
$3.54M
▲ 19.3% YoY Diluted EPS
$-0.17
Gross margin
54.1%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
CapsoVision, Inc (CV) Q2 2025 Earnings Call
Revenue
$3.31M
▲ 16.6% YoY Diluted EPS
$-2.02
Gross margin
54.6%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–6 of 6 webcasts